Mineralys Therapeutics Inc (NASDAQ: MLYS) kicked off on Monday, down -6.95% from the previous trading day, before settling in for the closing price of $14.54. Over the past 52 weeks, MLYS has traded in a range of $8.24-$18.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -170.42% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 19.87%. With a float of $40.61 million, this company’s outstanding shares have now reached $64.88 million.
In an organization with 51 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 37.70%, while institutional ownership is 65.84%. The most recent insider transaction that took place on Jun 13 ’25, was worth 165,931. In this transaction Chief Medical Officer of this company sold 11,366 shares at a rate of $14.60, taking the stock ownership to the 101,651 shares. Before that another transaction happened on Jun 13 ’25, when Company’s Officer proposed sale 11,366 for $14.60, making the entire transaction worth $165,931.
Mineralys Therapeutics Inc (MLYS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 19.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.14% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Take a look at Mineralys Therapeutics Inc’s (MLYS) current performance indicators. Last quarter, stock had a quick ratio of 26.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.74, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -2.94 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.73 million. That was inferior than the volume of 0.91 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.08%.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 52.16%, which indicates a significant increase from 33.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.49% in the past 14 days, which was lower than the 90.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.88, while its 200-day Moving Average is $13.00. However, in the short run, Mineralys Therapeutics Inc’s stock first resistance to watch stands at $14.34. Second resistance stands at $15.15. The third major resistance level sits at $15.60. If the price goes on to break the first support level at $13.08, it is likely to go to the next support level at $12.63. The third support level lies at $11.82 if the price breaches the second support level.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
The company with the Market Capitalisation of 881.82 million has total of 65,175K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -177,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -42,210 K.
